Compounds > 2,6-dimethyl-4-(2'-nitrosophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester
Page last updated: 2024-09-03

2,6-dimethyl-4-(2'-nitrosophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester and Diabetic Glomerulosclerosis

2,6-dimethyl-4-(2'-nitrosophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester has been researched along with Diabetic Glomerulosclerosis in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujii, S; Ikeda, Y; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kagami, S; Kihira, Y; Kobori, H; Miyamoto, L; Nuno, A; Sakurada, T; Tamaki, T; Tsuchiya, K; Urushihara, M; Yamano, N1

Other Studies

1 other study(ies) available for 2,6-dimethyl-4-(2'-nitrosophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester and Diabetic Glomerulosclerosis

ArticleYear
Nitrosonifedipine ameliorates the progression of type 2 diabetic nephropathy by exerting antioxidative effects.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Animals; Antioxidants; Cell Line; Diabetic Nephropathies; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nifedipine; Nitric Oxide Synthase Type III; Nitroso Compounds; Oxidative Stress

2014